vs
威伯科（CVGI）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是威伯科的1.3倍（$207.3M vs $154.8M），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -5.2%），威伯科自由现金流更多（$8.7M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -10.8%）
威伯科控股曾是总部位于美国的重型商用车零部件供应商，主打电子制动、稳定性控制、悬挂及传动自动化系统，产品广泛应用于卡车、巴士、挂车以及非道路作业车辆等各类商用车领域，是商用车行业重要的零部件提供商。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
CVGI vs RARE — 直观对比
营收规模更大
RARE
是对方的1.3倍
$154.8M
营收增速更快
RARE
高出31.1%
-5.2%
自由现金流更多
CVGI
多$109.5M
$-100.8M
两年增速更快
RARE
近两年复合增速
-10.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $154.8M | $207.3M |
| 净利润 | — | $-128.6M |
| 毛利率 | 9.7% | — |
| 营业利润率 | -1.2% | -54.7% |
| 净利率 | — | -62.0% |
| 营收同比 | -5.2% | 25.9% |
| 净利润同比 | — | 3.5% |
| 每股收益（稀释后） | — | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CVGIRARE
| Q4 25 | $154.8M | $207.3M | ||
| Q3 25 | $152.5M | $159.9M | ||
| Q2 25 | $172.0M | $166.5M | ||
| Q1 25 | $169.8M | $139.3M | ||
| Q4 24 | $163.3M | $164.6M | ||
| Q3 24 | $171.8M | $139.5M | ||
| Q2 24 | $193.7M | $147.0M | ||
| Q1 24 | $194.6M | $108.8M |
净利润CVGIRARE
| Q4 25 | — | $-128.6M | ||
| Q3 25 | $-7.1M | $-180.4M | ||
| Q2 25 | $-4.8M | $-115.0M | ||
| Q1 25 | $-4.3M | $-151.1M | ||
| Q4 24 | — | $-133.2M | ||
| Q3 24 | $9.5M | $-133.5M | ||
| Q2 24 | $-1.6M | $-131.6M | ||
| Q1 24 | $2.9M | $-170.7M |
毛利率CVGIRARE
| Q4 25 | 9.7% | — | ||
| Q3 25 | 10.5% | — | ||
| Q2 25 | 11.4% | — | ||
| Q1 25 | 10.5% | — | ||
| Q4 24 | 8.0% | — | ||
| Q3 24 | 9.6% | — | ||
| Q2 24 | 10.6% | — | ||
| Q1 24 | 11.9% | — |
营业利润率CVGIRARE
| Q4 25 | -1.2% | -54.7% | ||
| Q3 25 | -0.7% | -106.9% | ||
| Q2 25 | 0.5% | -64.8% | ||
| Q1 25 | 0.8% | -102.6% | ||
| Q4 24 | -3.2% | -74.3% | ||
| Q3 24 | -0.6% | -94.6% | ||
| Q2 24 | 0.5% | -79.1% | ||
| Q1 24 | 2.3% | -151.9% |
净利率CVGIRARE
| Q4 25 | — | -62.0% | ||
| Q3 25 | -4.6% | -112.8% | ||
| Q2 25 | -2.8% | -69.0% | ||
| Q1 25 | -2.5% | -108.5% | ||
| Q4 24 | — | -80.9% | ||
| Q3 24 | 5.5% | -95.7% | ||
| Q2 24 | -0.8% | -89.5% | ||
| Q1 24 | 1.5% | -156.8% |
每股收益（稀释后）CVGIRARE
| Q4 25 | — | $-1.28 | ||
| Q3 25 | — | $-1.81 | ||
| Q2 25 | — | $-1.17 | ||
| Q1 25 | — | $-1.57 | ||
| Q4 24 | — | $-1.34 | ||
| Q3 24 | — | $-1.40 | ||
| Q2 24 | $-0.05 | $-1.52 | ||
| Q1 24 | $0.09 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $421.0M |
| 总债务越低越好 | $104.9M | — |
| 股东权益账面价值 | $133.4M | $-80.0M |
| 总资产 | $391.7M | $1.5B |
| 负债/权益比越低杠杆越低 | 0.79× | — |
8季度趋势，按日历期对齐
现金及短期投资CVGIRARE
| Q4 25 | — | $421.0M | ||
| Q3 25 | — | $202.5M | ||
| Q2 25 | — | $176.3M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $174.0M | ||
| Q3 24 | — | $150.6M | ||
| Q2 24 | — | $480.7M | ||
| Q1 24 | — | $112.3M |
总债务CVGIRARE
| Q4 25 | $104.9M | — | ||
| Q3 25 | $108.2M | — | ||
| Q2 25 | $118.2M | — | ||
| Q1 25 | $117.4M | — | ||
| Q4 24 | $135.5M | — | ||
| Q3 24 | $128.8M | — | ||
| Q2 24 | $142.0M | — | ||
| Q1 24 | $155.7M | — |
股东权益CVGIRARE
| Q4 25 | $133.4M | $-80.0M | ||
| Q3 25 | $136.5M | $9.2M | ||
| Q2 25 | $142.6M | $151.3M | ||
| Q1 25 | $136.7M | $144.2M | ||
| Q4 24 | $135.6M | $255.0M | ||
| Q3 24 | $179.3M | $346.8M | ||
| Q2 24 | $169.6M | $432.4M | ||
| Q1 24 | $175.5M | $140.3M |
总资产CVGIRARE
| Q4 25 | $391.7M | $1.5B | ||
| Q3 25 | $400.3M | $1.2B | ||
| Q2 25 | $429.8M | $1.3B | ||
| Q1 25 | $419.8M | $1.3B | ||
| Q4 24 | $424.6M | $1.5B | ||
| Q3 24 | $495.3M | $1.5B | ||
| Q2 24 | $503.2M | $1.6B | ||
| Q1 24 | $509.2M | $1.3B |
负债/权益比CVGIRARE
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.79× | — | ||
| Q2 25 | 0.83× | — | ||
| Q1 25 | 0.86× | — | ||
| Q4 24 | 1.00× | — | ||
| Q3 24 | 0.72× | — | ||
| Q2 24 | 0.84× | — | ||
| Q1 24 | 0.89× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $12.3M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $8.7M | $-100.8M |
| 自由现金流率自由现金流/营收 | 5.6% | -48.6% |
| 资本支出强度资本支出/营收 | 2.3% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $34.0M | $-472.0M |
8季度趋势，按日历期对齐
经营现金流CVGIRARE
| Q4 25 | $12.3M | $-99.8M | ||
| Q3 25 | $-1.7M | $-91.4M | ||
| Q2 25 | $18.9M | $-108.3M | ||
| Q1 25 | $15.2M | $-166.5M | ||
| Q4 24 | $-26.6M | $-79.3M | ||
| Q3 24 | $-17.1M | $-67.0M | ||
| Q2 24 | $12.6M | $-77.0M | ||
| Q1 24 | $-2.4M | $-190.7M |
自由现金流CVGIRARE
| Q4 25 | $8.7M | $-100.8M | ||
| Q3 25 | $-3.5M | $-92.7M | ||
| Q2 25 | $17.4M | $-110.7M | ||
| Q1 25 | $11.4M | $-167.8M | ||
| Q4 24 | $-30.6M | $-79.5M | ||
| Q3 24 | $-20.3M | $-68.6M | ||
| Q2 24 | $6.4M | $-79.0M | ||
| Q1 24 | $-7.4M | $-193.9M |
自由现金流率CVGIRARE
| Q4 25 | 5.6% | -48.6% | ||
| Q3 25 | -2.3% | -58.0% | ||
| Q2 25 | 10.1% | -66.5% | ||
| Q1 25 | 6.7% | -120.5% | ||
| Q4 24 | -18.7% | -48.3% | ||
| Q3 24 | -11.8% | -49.2% | ||
| Q2 24 | 3.3% | -53.7% | ||
| Q1 24 | -3.8% | -178.2% |
资本支出强度CVGIRARE
| Q4 25 | 2.3% | 0.5% | ||
| Q3 25 | 1.2% | 0.8% | ||
| Q2 25 | 0.9% | 1.5% | ||
| Q1 25 | 2.2% | 1.0% | ||
| Q4 24 | 2.4% | 0.1% | ||
| Q3 24 | 1.9% | 1.2% | ||
| Q2 24 | 3.2% | 1.4% | ||
| Q1 24 | 2.6% | 3.0% |
现金转化率CVGIRARE
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -1.79× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.80× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CVGI
| Global Seating | $70.7M | 46% |
| Global Electrical Systems | $49.7M | 32% |
| Trim Systems And Components | $34.4M | 22% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
